...
首页> 外文期刊>Canadian journal of gastroenterology >Third-generation cephalosporin-resistant spontaneous bacterial peritonitis: A single-centre experience and summary of existing studies
【24h】

Third-generation cephalosporin-resistant spontaneous bacterial peritonitis: A single-centre experience and summary of existing studies

机译:第三代头孢菌素耐药性自发性细菌性腹膜炎:单中心经验和现有研究总结

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Spontaneous bacterial peritonitis (SBP) is the most prevalent bacterial infection in patients with cirrhosis. Although studies from Europe have reported significant rates of resistance to third-generation cephalosporins, there are limited SBP-specific data from centres in North America. OBJECTIVE: To evaluate the prevalence of, predictors for and clinical impact of third-generation cephalosporin-resistant SBP at a Canadian tertiary care centre, and to summarize the data in the context of the existing literature. METHODS: SBP patients treated with both antibiotics and albumin therapy at a Canadian tertiary care hospital between 2003 and 2011 were retrospectively identified. Multivariate logistic regression was used to determine independent predictors of third-generation cephalosporin resistance and mortality. RESULTS: In 192 patients, 25% of infections were nosocomial. Forty per cent (77 of 192) of infections were culture positive; of these, 19% (15 of 77) were resistant to third-generation cephalosporins. The prevalence of cephalosporin resistance was 8% with community-acquired infections, 17% with health care-associated infections and 41% with nosocomial acquisition. Nosocomial acquisition of infection was the only predictor of resistance to third-generation cephalosporins (OR 4.0 [95% CI 1.04 to 15.2]). Thirty-day mortality censored for liver transplantation was 27% (50 of 184). In the 77 culture-positive patients, resistance to third-generation cephalosporins (OR 5.3 [1.3 to 22]) and the Model for End-stage Live Disease score (OR 1.14 [1.04 to 1.24]) were independent predictors of 30-day mortality. CONCLUSIONS: Third-generation cephalosporin-resistant SBP is a common diagnosis and has an effect on clinical outcomes. In an attempt to reduce the mortality associated with resistance to empirical therapy, high-risk subgroups should receive broader empirical antibiotic coverage.
机译:背景:自发性细菌性腹膜炎(SBP)是肝硬化患者中最普遍的细菌感染。尽管来自欧洲的研究报告了对第三代头孢菌素的耐药率很高,但北美中心的SBP特异性数据有限。目的:在加拿大三级护理中心评估第三代头孢菌素耐药性SBP的患病率,预测因素及其临床影响,并在现有文献中总结数据。方法:回顾性分析2003年至2011年间在加拿大三级医院接受抗生素和白蛋白治疗的SBP患者。多因素logistic回归用于确定第三代头孢菌素耐药性和死亡率的独立预测因子。结果:在192例患者中,有25%的感染是医院感染。感染的40%(192个中的77个)为培养阳性;其中,有19%(77个中的15个)对第三代头孢菌素具有抗药性。在社区获得性感染中,头孢菌素耐药性的患病率为8%,在与卫生保健相关的感染中,感染率为17%,在医院获得性感染时为41%。医院内感染的获得是对第三代头孢菌素耐药的唯一预测因子​​(OR 4.0 [95%CI 1.04至15.2])。肝移植检查的30天死亡率为27%(184个中的50个)。在77名文化阳性患者中,对第三代头孢菌素的耐药性(OR 5.3 [1.3至22])和终末期活病评分模型(OR 1.14 [1.04至1.24])是30天死亡率的独立预测因子。结论:第三代头孢菌素耐药性SBP是常见诊断,对临床结局有影响。为了降低与经验疗法抗性相关的死亡率,高风险亚组应接受更广泛的经验抗生素治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号